These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10814923)

  • 21. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.
    Moen O; Høgåsen K; Fosse E; Dregelid E; Brockmeier V; Venge P; Harboe M; Mollnes TE
    Ann Thorac Surg; 1997 Jan; 63(1):105-11. PubMed ID: 8993250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
    Pekna M; Borowiec J; Fagerhol MK; Venge P; Thelin S
    Scand J Thorac Cardiovasc Surg; 1994; 28(1):5-11. PubMed ID: 7939508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration.
    Defraigne JO; Pincemail J; Larbuisson R; Blaffart F; Limet R
    Ann Thorac Surg; 2000 Apr; 69(4):1084-91. PubMed ID: 10800798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations.
    Videm V; Svennevig JL; Fosse E; Semb G; Osterud A; Mollnes TE
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):806-13. PubMed ID: 1548925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits.
    Jansen PG; te Velthuis H; Huybregts RA; Paulus R; Bulder ER; van der Spoel HI; Bezemer PD; Slaats EH; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1995 Sep; 110(3):829-34. PubMed ID: 7564452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).
    Hazama S; Eishi K; Yamachika S; Noguchi M; Ariyoshi T; Takai H; Odate T; Matsukuma S; Onohara D; Yanatori M
    Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):90-6. PubMed ID: 15209550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass.
    Gu YJ; van Oeveren W; Akkerman C; Boonstra PW; Huyzen RJ; Wildevuur CR
    Ann Thorac Surg; 1993 Apr; 55(4):917-22. PubMed ID: 8466349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with heparin-coated cardiopulmonary bypass circuits.
    Pradhan MJ; Fleming JS; Nkere UU; Arnold J; Wildlevuur CR; Taylor KM
    Perfusion; 1991; 6(3):235-42. PubMed ID: 10149510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery.
    Olsson C; Siegbahn A; Henze A; Nilsson B; Venge P; Joachimsson PO; Thelin S
    Scand Cardiovasc J; 2000; 34(1):33-40. PubMed ID: 10816058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved blood cellular biocompatibility with heparin coated circuits during cardiopulmonary bypass.
    Belboul A; Akbar O; Löfgren C; Jungbeck M; Storm C; Roberts A
    J Cardiovasc Surg (Torino); 2000 Jun; 41(3):357-62. PubMed ID: 10952323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
    Videm V; Mollnes TE; Bergh K; Fosse E; Mohr B; Hagve TA; Aasen AO; Svennevig JL
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):803-9. PubMed ID: 10096977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
    J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of heparin coated circuits upon metabolism in vital organs: effect upon cerebral and renal function during and after cardiopulmonary bypass.
    de Vroege R; Stooker W; van Oeveren W; Bakker EW; Huybregts RA; van Klarenbosch J; van Kamp GJ; Hack CE; Eijsman L; Wildevuur CR
    ASAIO J; 2005; 51(1):103-9. PubMed ID: 15745143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
    Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
    Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression changes in leukocytes during cardiopulmonary bypass are dependent on circuit coating.
    Seeburger J; Hoffmann J; Wendel HP; Ziemer G; Aebert H
    Circulation; 2005 Aug; 112(9 Suppl):I224-8. PubMed ID: 16159821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig.
    Nilsson L; Storm KE; Thelin S; Bagge L; Hultman J; Thorelius J; Nilsson U
    Artif Organs; 1990 Feb; 14(1):46-8. PubMed ID: 2302076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery.
    Thiara AS; Mollnes TE; Videm V; Andersen VY; Svennevig K; Kolset SO; Fiane AE
    Perfusion; 2011 Mar; 26(2):107-14. PubMed ID: 21177724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.
    Ozawa T; Yoshihara K; Koyama N; Yamazaki S; Takanashi Y
    Jpn J Thorac Cardiovasc Surg; 1999 Dec; 47(12):592-9. PubMed ID: 10658376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.